
Organic Process Research and Development p. 1897 - 1904 (2012)
Update date:2022-08-25
Topics:
Gillmore, Adam T.
Badland, Matthew
Crook, Clare L.
Castro, Nieves M.
Critcher, Douglas J.
Fussell, Steven J.
Jones, Katherine J.
Jones, Matthew C.
Kougoulos, Eleftherios
Mathew, Jinu S.
McMillan, Lynne
Pearce, John E.
Rawlinson, Fiona L.
Sherlock, Alexandra E.
Walton, Robert
Novel PARP inhibitor 1 is a promising new candidate for treatment of breast and ovarian cancer. A modified synthetic route to 1 has been developed and demonstrated on 7 kg scale. In order to scale up the synthesis to multikilogram scale, several synthetic challenges needed to be overcome. The key issues included significant thermal hazards present in a Leimgruber-Batcho indole synthesis, a low-yielding side-chain installation, a nonrobust Suzuki coupling and hydrogen cyanide generation during a reductive amination. In addition to these issues, changing from intravenous to oral delivery required a new salt form and therefore a new crystallization procedure. This contribution describes development work to solve these issues and scaling up of the new process in the pilot plant.
View More
HaiNan Periwinkle Pharmaceutical Co.,Ltd.
website:http://www.cchpharm.com/en/index.html
Contact:020-82208978
Address:Gongye road,Wuzhishan city,HaiNan province
Contact:+86-532-80762375
Address:No. 6, Hongkong Middle Road, Qingdao, China
Shanghai agrotree chemical co.,ltd.
Contact:+86-21-50117563
Address:Room 8A,liangfeng building,No.8 dongfang RD.pudong,shanghai,China
JiangXi Hong Run Chemical Co., Ltd
Contact:+86-0791-88521351
Address:XingHuo industrial zone in YongXiu county
Chengda Pharmaceuticals Co., Ltd.
Contact:+86-573-84601188
Address:hengshan Road 5# in Jiashan, zhejiang
Doi:10.1021/op050044y
(2005)Doi:10.1021/jacs.9b00341
(2019)Doi:10.1016/S0040-4039(00)70378-9
(1965)Doi:10.1039/c9nj02727k
(2019)Doi:10.1021/jacs.9b02505
(2019)Doi:10.1002/cplu.201500282
(2015)